Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Financial Officer | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,166 |
Ending reported balance
After 2026-08-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-04 · Sale · Disposed 1,794 · Balance 43,133 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-08-04 · Sale · Disposed 2,967 · Balance 40,166 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: Represents the weighted average sale price. The lowest price at which shares were sold was $24.42 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $38.05 | $15,219.00 |
DisclosureSEC source: 0001209191-21-012668 · doc4.xml · nonDerivative · entry 6 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.74 and the highest price at which shares were sold was $38.43. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 666 | $36.91 | $24,581.26 |
DisclosureSEC source: 0001209191-21-012668 · doc4.xml · nonDerivative · entry 5 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.72 and the highest price at which shares were sold was $37.30. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,725 | $36.00 | $206,109.16 |
DisclosureSEC source: 0001209191-21-012668 · doc4.xml · nonDerivative · entry 4 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,066 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.62 and the highest price at which shares were sold was $36.62. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,652 | $35.10 | $128,200.54 |
DisclosureSEC source: 0001209191-21-012668 · doc4.xml · nonDerivative · entry 3 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,791 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $34.60 and the highest price at which shares were sold was $35.57. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,140 | $34.24 | $107,511.09 |
DisclosureSEC source: 0001209191-21-012668 · doc4.xml · nonDerivative · entry 2 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,443 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $33.59 and the highest price at which shares were sold was $34.59. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 13,583 | $0.84 | $11,409.72 |
DisclosureSEC source: 0001209191-21-012668 · doc4.xml · nonDerivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 00:27 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $38.97 | $0.00 |
DisclosureSEC source: 0001209191-21-010445 · doc4.xml · derivative · entry 1 van Houte Hans · CIK 0001817217 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning March 11, 2021 until the option is fully vested on February 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.